Advertisement

Molecular Features and Treatment Modalities of “Classic” Versus Human Papilloma Virus-Associated Head and Neck Cancer

Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

Human papilloma virus (HPV)-associated squamous cell carcinoma of the head and neck (SCCHN) represents a unique disease entity, with distinct epidemiological and molecular characteristics from those of tobacco- and alcohol-related SCCHN, resulting in different biological and clinical tumor behavior. The implication of HPV in the pathogenesis of a subset of SCCHN patients has generated the hypothesis that vaccine-induced immune response against HPV may provide substantial clinical benefit; however, the impact of prophylactic HPV vaccines on the incidence of HPV-associated SCCHN remains to be clarified. Preliminary evidence also shows that therapeutic HPV vaccines are able to induce potent, HPV-specific, immune responses that correlate with tumor regression, and therapeutic HPV vaccines are currently undergoing intense investigation in early clinical trials, especially in the subset of patients with oropharyngeal cancer. The question of de-escalation of treatment in the favorable prognosis subset of patients with HPV-associated disease is also currently being explored in clinical trials in an effort to minimize unnecessary toxicity without compromising therapeutic efficacy.

Keywords

Squamous cell cancer of the head and neck Human papilloma virus HPV-related vaccine Oropharyngeal cancer Dose de-escalation 

References

  1. 1.
    Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–7.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Bonner JA, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med. 2007;357(18):1872–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004;96(13):998–1006.PubMedCrossRefGoogle Scholar
  6. 6.
    Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–54.Google Scholar
  7. 7.
    Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011;53 Suppl 1:S5–11.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell. 2006;98(8):479–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27(35):5911–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62.CrossRefGoogle Scholar
  12. 12.
    Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010;70(9):1079–98.PubMedCrossRefGoogle Scholar
  14. 14.
    Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Goodwin EC, Yang E, Lee CJ, et al. Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A. 2000;97(20):10978–83.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Hayward SD, Liu J, Fujimuro M. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE. 2006;2006(335):re4.Google Scholar
  17. 17.
    Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49(1):79–85PubMedCrossRefGoogle Scholar
  18. 18.
    Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.PubMedCrossRefGoogle Scholar
  19. 19.
    Leemans CR, Braakhuis BJ, Brakenhoff RH, et al. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Maeda H, Kubo K, Sugita Y, et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res. 2005;33(6):647–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Marur S, Li S, Cmelak A, et al, E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). J Clin Oncol. 31, 2013 (suppl; abstr 6005).Google Scholar
  22. 22.
    Mehra R, Egloff AM, Li S, et al. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol. 31, 2013 (suppl; abstr 6006).Google Scholar
  23. 23.
    Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 2002;102(2):152–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Morris LG, Taylor BS, Bivona TG, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011;108(47):19024–9.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res. 1993;53(18):4189–96.PubMedGoogle Scholar
  27. 27.
    Nickoloff BJ, Qin JZ, Chaturvedi V, et al. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ. 2002;9(8):842–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–61.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer 2008; Res. 2006;12(5):1441–6.Google Scholar
  32. 32.
    Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer. 2008;122(5):1189–94.Google Scholar
  33. 33.
    Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Rampias T, Boutati E, Pectasides E, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010;8(3):433–43.PubMedCrossRefGoogle Scholar
  35. 35.
    Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28(27):4142–8.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Human vaccines. 2011;7(2):161–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Rothenberg SM, Ellisen LW. 2012 The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012;122(6):1951-7.Google Scholar
  38. 38.
    Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Strati K, Lambert PF. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res. 2007;67(24):11585–93.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Tan TM, Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 1995;55(20):4599–605.PubMedGoogle Scholar
  41. 41.
    Tumban E, Peabody J, Peabody DS, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PloS one. 2011;6(8):e23310.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Van Tine BA, Dao, Wu SY, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Natl Acad Sci U S A. 2004;101(12):4030–5.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PloS one. 2011;6(5):e19252.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.PubMedCrossRefGoogle Scholar
  45. 45.
    Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res. 2004;10(17):5684–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736–47.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.University of Athens School of MedicineAthensGreece
  2. 2.National Kapodistrian University of AthensAthensGreece

Personalised recommendations